BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 15, 2025
Home » Topics » Cardiovascular, BioWorld MedTech

Cardiovascular, BioWorld MedTech
Cardiovascular, BioWorld MedTech RSS Feed RSS

The G18

Nov. 23, 2011
By Amanda Pedersen
So far I’ve chronicled my visit to Canada by focusing on what I’ve learned so far about the country’s focused efforts on growing its medical device industry – which is, of course, the primary purpose of the Advanced Medical Devices Media Tour, organized by the Ontario Ministry of Economic Development and Innovation (MEDI). But in addition...
Read More

Being there first: Personalized medicine and the investor

Nov. 10, 2011
By Mark McCarty
I don't directly invest in med-tech, but attending Transcatheter Cardiovascular Therapeutics for five years makes me wonder how an investor separates winners and losers. I know TCT 2011 has both, but which are which? Asking about the patient population is just the start of the investor conversation, but in an age in which indications for use are becoming increasingly narrow, it's probably the last question, too. After all, we have radio-frequency ablation devices approved for paroxysmal atrial fibrillation, but not for persistent or long-standing afib....
Read More

Medtronic plans to enter ED market

Nov. 4, 2011
By Omar Ford
Medtronic has the potential to be a trend setter with its attempt to have drug eluting stents (DES) treat erectile dysfunction (ED). The device maker recently moved one step closer in this effort as it reported that it had completed its ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), feasibility study. The device, which hasn't been named yet, will be inserted into the pelvic area of the body. More specifically the stent is delivered using a catheter threaded up to the pelvis, where the pudendal artery is located. It...
Read More

A tinkerer at heart, Wilson Greatbatch epitomized what that means to medicine

Oct. 4, 2011
By Jim Stommen
A prolific inventor who died last week in upstate New York at the age of 92, Wilson Greatbatch is credited with more than 325 patents, including coming up with the first practical implantable pacemaker. Besides being memorialized for those breakthroughs, he truly should be viewed as an inveterate tinkerer who as much as any single individual represents the very best of what that term means to medical innovation. While the invention of the...
Read More

The Good, the Bad and the Ugly: Third-party coverage requests

Sep. 30, 2011
By Mark McCarty
As a member of the trade press, I get a kick out of how routinely some people in the mainstream media and the population at large routinely assume that device makers are driven by greed and that doctors are morally flawless creatures who spend all their spare time pondering the public weal and woe, continuously devising ways to ensure their passage through the Pearly Gates with constant acts of selflessness. And then I see the parties weighing in on the question of Medicare coverage for the Sapien aortic valve made by...
Read More

Could Medtronic eventually shed Infuse?

Sep. 26, 2011
By Omar Ford
After Johnson & Johnson (J&J, New Brunswick, New Jersey) said that it was going to discontinue its work in the drug eluting stent (DES) market, my eyes then began to focus on Medtronic (Minneapolis), which has recently taken a beating in the wallet and court of public opinion with its bone growth product, Infuse. I began asking myself how much longer before Medtronic finally abandons ship on this application. I mean if there ever was a shining example of a device that has caused problems for a company then Infuse is it. The med-tech juggernaut was dealt what one would...
Read More

MedCath’s rise and fall a reflection of the changing realities of a fickle healthcare market

Sep. 14, 2011
By Holland Johnson
Back in the early days of Medical Device Daily – in fact, it might even have been in the relatively brief very early period of time when the new publication was known as Medical Device Week – it’s likely that few if any healthcare-related companies got more frequent mention in our pages than MedCath. Thinking back on that time, it seems like news stories on the high-flying operator of heart-focused specialty hospitals were appearing in MDW and then MDD with amazing regularity. It was “MedCath reported this week plans to open a new hospital in . . .” or “MedCath...
Read More

Top Five Things to Watch for in 2011

Aug. 31, 2011
By Mark McCarty
In the world of diagnostic and therapeutic devices, 2011 has already been a busy year, but a third of the year remains. There are still numerous developments that will trigger cheer and jeers, depending on where you sit. This is not an exhaustive list of things that could arise in the last half of this year, but these are all pretty big, and a lot of people will be watching carefully. FDA meeting on IOM 510(k) report: FDA recently invited all interested parties to talk about the recommendations made recently by the Institute of Medicine regarding the 510(k) device clearance...
Read More

FDA to small firms: Thanks but no thanks

July 22, 2011
By Mark McCarty
There's nothing like having siblings who are several years older and in their teens. You admire them for being so mature and so big. When you wanted to hang out with them, though, maybe they told you to buzz off. If you work for a firm intent on bringing a PMA device to market, FDA's insistence on a 1,000-patient post-approval study (PAS) for the Sapien transcatheter valve might have given you a bad case of deja vu because a small firm might not be able to get investors on board, even...
Read More

J&J exits DES market

July 7, 2011
By Omar Ford
A few weeks ago, I made the mistake of going into the gym around 6 p.m. That's the time when all the body builders and athletes tend to circulate in the area. I also made the mistake of getting on the treadmill next to someone who obviously looks like he runs track for a living. After seeing him run close to 10 mph without breaking a sweat - and I was struggling to do six -  I left the gym dejected. The competition in there was just too great. How could I possibly keep up with someone who can do a mile...
Read More
Previous 1 2 … 84 85 86 87 88 89 90 91 92 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 14, 2025.
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • Noah Medical

    ​FDA floods Noah Medical with multi-deviation warning letter

    BioWorld MedTech
    Companies new to the world of U.S. FDA regulation are often unaware of how detailed the agency’s inspections are, which might be the case with the...
  • Scorpion Therapeutics patents p53 Y220 mutant activators

    BioWorld Science
    Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing